Abstract library

44 results for "Cives".
#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).
Conference: 17th Annual ENETS Conference (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Costello Medical
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
#792 Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors
Introduction: Pasireotide LAR is a novel SSA with avid binding to SSTR 1, 2, 3 and 5. It has never been investigated in treatment naïve patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Jonathan R Strosberg
Authors: Cives M, Kunz P, Nguyen P, Jump H, ...
#905 Cancer-Associated-Fibroblasts in Neuroendocrine Neoplasms: A Role in Cancer Progression
Introduction: Cancer-associated-fibroblasts (CAFs) secrete soluble factors that enhance tumor growth and invasion. Neuroendocrine tumor (NET) cells recruit fibroblasts within the lesional sites.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Francesca Maria Rizzo
#908 Role of Epithelial-to-Mesenchymal Transition Markers in Predicting Bone and Visceral Metastases from NETs
Introduction: Epithelial-to-mesenchymal transition (EMT) of tumor cells has been recently postulated as a pivotal mechanism driving metastatic spread.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Valeria Simone
Keywords: EMT, biomarker
#1179 A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results
Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives
Authors: Cives M, Strosberg J, Campos T, Weber T, ...
#1181 Significance of Ectopic Lymph Node-Like Structures in Neuroendocrine Tumors of the Small Bowel
Introduction: The formation of extranodal tertiary lymphoid follicles and lymphoid cell aggregates has been described in nonmalignant conditions including autoimmune diseases and chronic inflammation as well as in cancer. Tumor-induced lymph node-like structures (LLS) participate in the host’s antitumor immune response by driving intratumoral immune cell priming
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Dr. Mauro Cives
#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy
Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Dr. Mauro Cives
#1520 Osteotropism of NETs: Role of the SDF1/CXCR4 Axis in Regulating EMT
Introduction: NETs metastasize to the bone in up to 20% of patients. The SDF1/CXCR4 axis is a key determinant of osteotropism, and we showed that NETs overexpressing CXCR4 are more likely to develop bone metastases.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Valeria Simone
Keywords: emt, cxcr4
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team